This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sterba, M Articles by Gersl, V Search for Related Content PubMed PubMed Citation Articles by Sterba, M Articles by Gersl, V Social Bookmarking                   What's this?

Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits

Faculty of Medicine in Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic; Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University in Prague, Simkova 870, 500 38 Hradec Králové 1, Czech Republicsterbam{at}lfhk.cuni.cz

T Simunek

Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Hradec Králová, Czech Republic

Y Mazurová

M Adamcová

O Popelová

J Kaplanová

Faculty of Medicine in Hradec Králové, Charles University in Prague, Hradec Králová, Czech Republic

P Ponka

Lady Davis Institute for Medical Research, McGill University, Montreal, Canada

V Gersl

Faculty of Medicine in Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic

Recently, pyridoxal 2-chlorobenzoyl hydrazone (o-108) has been identified as an effective iron chelator [Link et al., Blood 2003; 101: 4172–79]. Since chronic treatment would be necessary in its potential indications, in the present study, the safety and tolerability of this agent after repeated administration was determined. Three doses of o-108 (25, 50, 100 mg/kg, in 10% Cremophor EL) were administered intraperitoneally, once weekly, for 10 weeks to three groups (n–5 each) of Chinchilla male rabbits. The effects on biochemical, haematological and cardiovascular parameters were examined during the experiment; histopathological examination was performed at the end of the experiment. Results were compared with control (saline 2 mL/kg, n–11) and vehicle groups (10% Cremophor EL, 2 mL/kg, n–12). No premature deaths occurred; the well-being of animals was evidenced by their body weight gain, although lower gain was observed with the highest dose (100 mg/kg). Significant elevations of cardiac troponin T plasma concentrations were observed with the highest dose of o-108, but no abnormalities were found in the cardiovascular function and only minor and inconsistent changes in haematological and biochemical parameters were observed. Histopathological examinations of selected organs revealed only weak and reversible changes through all studied groups. Thus, the data from this study suggest that o-108 remains a promising drug from the standpoint of the possibility of its repeated administration and warrants further investigation.

Key Words: iron chelator • o-108 • pyridoxal 2-chlorobenzoyl hydrazone

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Sterba, O. Popelova, T. Simunek, Y. Mazurova, A. Potacova, M. Adamcova, H. Kaiserova, P. Ponka, and V. Gersl Cardioprotective Effects of a Novel Iron Chelator, Pyridoxal 2-Chlorobenzoyl Hydrazone, in the Rabbit Model of Daunorubicin-Induced Cardiotoxicity J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1336 - 1347. [Abstract] [Full Text] [PDF]